ClinicalTrials.gg
RecruitingNCT05636384HOMECAREUpdated Dec 5, 2022

SupporTive Care At Home Research for Patients With Advanced Cancer (STAHR-cancer)

An interventional study of Home-based care in Malignant Neoplasm, Home Care Services and Quality of LIfe, sponsored by Seoul National University Hospital. Recruiting at 6 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
396
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Study summary

To test the effects of home-based care on unplanned hospitalization within 6 months among advanced cancer patients with decreased performance status. Home-based care includes education for patients and their family caregivers, home visits by specialized home-based medical staff, and regular status check-ups.

Read the detailed description

This study is a cluster, non-randomized controlled trial to test the effects of home-based care on unplanned hospitalization in 6 months among advanced cancer patients with decreased performance status. Home-based care includes education for patients and their family caregivers, home visits by specialized home-based medical staff, and regular status check-up. We are recruiting the study participants from 6 institutions, aiming for 396 cancer patients.

Participants for the intervention group will be recruited from Seoul National University Hospital, Chung-ang University Hospital, and Dongguk University Ilsan Hospital. Participants for the control group will be recruited from Kyung Hee University Medical Center, CHA Bundang Medical Center, and Seoul National University Bundang Hospital.

02

Conditions studied

  • Malignant Neoplasm
  • Home Care Services
  • Quality of LIfe
  • Unplanned Hospitalization

Browse trials for

03

In context

Neoplasms

9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.

This study's planned enrollment of 396 is above the median of 50 across 7,429 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,897 studies on the registry; 273 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Both the patient and their family caregiver must meet the criteria to be considered for this research.

  1. Patient

    1. A person who has an advanced-stage solid cancer diagnosis (ICD-10 code C00-C70); A person who is receiving or planning to receive cancer treatment
    2. A person who meets one of the following conditions

      1. Has been evaluated as having ECOG performance status 2
      2. Has been evaluated as having ECOG performance status 1 and is over 70 years of age
    3. A person who wishes to stay at home
    4. A person whose family caregiver resides at home
    5. A person who wishes to participate in the research
  2. Family Caregiver

    1. A family* member of the patient

      * Family: refers to the patient's spouse (including a common-law partner), descendants and their spouses up to the second degree, siblings and their spouses, and relatives and their spouses up to the eighth degree.

    2. A person who meets one of the following conditions:

      1. Lives with the patient (patient's household member)
      2. Does not live with the patient, but visits the patient's home more than three times a week
    3. A person who wants the patient to stay at home
    4. A person who can communicate easily with medical staff
    5. A person who wishes to participate in the research

Exclusion criteria

Exclusion Criteria:

If either the patient or the family caregiver meets any one of these criteria, they are excluded from the study.

  1. Patient

    1. A person who cannot speak, hear, or read Korean
    2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health
    3. A person residing outside the range that can be visited by the respective medical institution (the conditions for distance are to be specified by each medical institution)*

      * This condition is not applicable for the control group.

    4. A person who has used hospital- or home-type hospice and palliative care services
    5. A person who is under the age of 19
  2. Family Caregiver

    1. A person who cannot speak, hear, or read Korean
    2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health
    3. A person under the age of 19
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients enrolled in the intervention cluster (institution) are given specialized home-based medical care based on a specialized home-based medical team approach.

    Other: Home-based care

  • No intervention
    Control

    Patients enrolled in the control cluster (institution) are only given the educational materials. Except for the home-based care intervention, usual care for advanced cancer patients was not restricted for these patients.

Interventions

  • OtherHome-based care

    Home-based medical care is based on a specialized home-based medical team approach, including following: 1. Specialized Home-Based Medical Team Approach 2. Initial Assessment and Education 3. Initial Home Visits and Education 4. Multidisciplinary Team Meeting 5. Regular Assessment After the Initial Visit

06

What researchers measure

Primary outcomes

  1. Unplanned hospitalization

    1. admission to the enrolled hospital to treat unexpected symptoms or medical conditions (not including planned admission for chemotherapy or admission for planned surgery or intervention) 2. admission to a hospital other than the enrolled hospital 3. admission to a nursing hospital for a duration of less than 4 weeks.

    Time frame: within 6 months following enrollment

Secondary outcomes

  1. Patient medical utilization

    The total number of hospital utilization, including hospitalization, emergency room visit, and clinic visits

    Time frame: within 6 months following enrollment

  2. Hospitalization

    the number of hospitalization

    Time frame: within 6 months following enrollment

  3. ER visits

    the number of emergency room visits

    Time frame: within 6 months following enrollment

  4. Healthcare use

    the number of healthcare use for severe diseases

    Time frame: within 6 months following enrollment

  5. Patient end-of-life care: ICU admission

    ICU admission one month before death

    Time frame: within 1 month before death

  6. Patient end-of-life care: ventilator treatment

    Mechanical ventilator apply one month before death

    Time frame: within 1 month before death

  7. Patient end-of-life care: an advance directive

    Completion of advance medical directives within 1 month before death

    Time frame: within 1 month before death

  8. Quality of life of patient - ESAS

    Modified Edmonton Symptom Assessment System (ESAS) of patient

    Time frame: within 6 months following enrollment

  9. Quality of life of patient - EQ-5D

    Euro-Quality of Life-5 Dimension (EQ-5D) of patient

    Time frame: within 6 months following enrollment

  10. Depressive symptom of patient

    Patient Health Questionnaire-9 (PHQ-9) of patient

    Time frame: within 6 months following enrollment

  11. Satisfaction with services (patient)

    Satisfaction of the study participant (patient) with the service in this study, evaluated by questionnaire

    Time frame: within 6 months following enrollment

  12. Quality of life of family caregiver

    Euro-Quality of Life-5 Dimension (EQ-5D) of family caregiver

    Time frame: within 6 months following enrollment

  13. Care burden of family caregiver

    The Korean version of Caregiver Reaction Assessment (CRA-K) of family caregiver

    Time frame: within 6 months following enrollment

  14. Depressive symptom of family caregiver

    Patient Health Questionnaire-9 (PHQ-9) of family caregiver

    Time frame: within 6 months following enrollment

  15. Caring competency of family caregiver

    Caring competency of family caregiver, measured by questionnaire

    Time frame: within 6 months following enrollment

  16. Satisfaction with services (family caregiver)

    Satisfaction of the study participant (family caregiver) with the service in this study, evaluated by questionnaire

    Time frame: within 6 months following enrollment

  17. Expenses

    medical expenses, care expenses

    Time frame: within 6 months following enrollment

07

Study locations

6 of 6 sites recruiting
  • Dongguk University Medical Center
    Goyang-si, Gyeonggi-do, South Korea
    • Do yeun Kim, MD · Contact
    Recruiting
  • Bundang CHA Hospital
    Seongnam-si, Gyeonggi-do, South Korea
    • Beodeul Kang, MD · Contact
    Recruiting
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do, South Korea
    • Yu Jung Kim, MD · Contact
    Recruiting
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
  • Chung-Ang University Hosptial
    Seoul, South Korea
    • In Gyu Hwang, MD · Contact
    Recruiting
  • Kyung Hee University Hospital
    Seoul, South Korea
    • Sun Kyung Baek, MD · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05636384
Collaborators
Chung-Ang University Hospital, DongGuk University, Kyung Hee University Hospital, Bundang CHA Hospital, Seoul National University Bundang Hospital
Responsible party
BeLong Cho (Professor, Seoul National University Hospital) — Principal investigator
First posted
Dec 5, 2022
Start date
Jul 25, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 5, 2022

Study contacts

Ga-Young Lee
Contact
yoyo4284@snu.ac.kr
82-10-6527-3066
So-Hee Kim
Contact
sh6487@snu.ac.kr
Belong Cho, MD, MPH, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion